Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Return on Sales (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed Return on Sales for 9 consecutive years, with 0.06% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 3.0% year-over-year to 0.06%, compared with a TTM value of 0.06% through Dec 2025, down 1.0%, and an annual FY2025 reading of 0.44%, up 50.0% over the prior year.
  • Return on Sales was 0.06% for Q4 2025 at VYNE Therapeutics, up from 0.08% in the prior quarter.
  • Across five years, Return on Sales topped out at 75.08% in Q1 2022 and bottomed at 74.66% in Q4 2022.
  • Average Return on Sales over 5 years is 7.7%, with a median of 0.15% recorded in 2023.
  • The sharpest move saw Return on Sales soared 11714bps in 2022, then crashed -7518bps in 2023.
  • Year by year, Return on Sales stood at 11.71% in 2021, then plummeted by -537bps to 74.66% in 2022, then skyrocketed by 99bps to 0.49% in 2023, then skyrocketed by 80bps to 0.1% in 2024, then soared by 34bps to 0.06% in 2025.
  • Business Quant data shows Return on Sales for VYNE at 0.06% in Q4 2025, 0.08% in Q2 2025, and 0.04% in Q1 2025.